Two phase III studies of Xiaflex show efficacy in Peyronie's disease.- Endo International
Xiaflex is an FDA-approved treatment for adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Changes from baseline and from the previous penile curvature measurement were calculated after each of the four treatment cycles (weeks 6, 12, 18 and 24). CCH injections were administered in up to four treatment cycles at 6-week intervals; each cycle included two injections 1-3 days apart. For all patients, treatment included penile plaque modeling. Data support that incremental benefits were obtained from each of the four CCH treatment cycles administered to men with PD. Results may suggest incremental benefits with performing a full series of four CCH injections and penile modeling, even among men who were initially considered non-responders (achieved <20% reduction in penile curvature after two cycles of injections).></20%>
Xiaflex is contraindicated in the treatment of Peyronie's plaques that involve the penile urethra due to potential risk to this structure and in patients with a history of hypersensitivity to Xiaflex or to collagenase used in any other therapeutic application or application method.
Related news and insights
CTI BioPharma Corp. announced the FDA has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109 l.
ImmunoGen announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of IMGN 853 (mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FR?)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).